These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 36351537)

  • 1. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
    Cheng Y; Bu D; Zhang Q; Sun R; Lyle S; Zhao G; Dong L; Li H; Zhao Y; Yu J; Hao X
    J Adv Res; 2023 Sep; 51():121-134. PubMed ID: 36351537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty Acid Metabolism Signature Contributes to the Molecular Diagnosis of a Malignant Gastric Cancer Subtype with Poor Prognosis and Lower Mutation Burden.
    Chen Z; Cheng G
    Recent Pat Anticancer Drug Discov; 2024; 19(5):666-680. PubMed ID: 37691229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.
    Li Z; Jia Y; Zhu H; Xing X; Pang F; Shan F; Li S; Wang D; Zhao F; Ma T; Wang S; Ji J
    Gastric Cancer; 2021 Nov; 24(6):1342-1354. PubMed ID: 34406546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
    Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
    Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
    Li X; Pasche B; Zhang W; Chen K
    JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics.
    Wang H; Ding Y; Chen Y; Jiang J; Chen Y; Lu J; Kong M; Mo F; Huang Y; Zhao W; Fang P; Chen X; Teng X; Xu N; Lu Y; Yu X; Li Z; Zhang J; Wang H; Bao X; Zhou D; Chi Y; Zhou T; Zhou Z; Chen S; Teng L
    Gastric Cancer; 2021 Nov; 24(6):1227-1241. PubMed ID: 34095982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
    Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
    Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
    Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
    Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
    Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
    J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational signatures in 175 Chinese gastric cancer patients.
    Liu F; Hu N; Jiang K; Liu H; Wang M; Hu Y; Zhang T; Wu HH; Yang H; Weng H; Dong P; Giffen C; Zhu B; Lee MP; Abnet CC; Taylor PR; Liu Y; Liu Y; Goldstein AM
    BMC Cancer; 2024 Sep; 24(1):1208. PubMed ID: 39350044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actionable gene-based classification toward precision medicine in gastric cancer.
    Ichikawa H; Nagahashi M; Shimada Y; Hanyu T; Ishikawa T; Kameyama H; Kobayashi T; Sakata J; Yabusaki H; Nakagawa S; Sato N; Hirata Y; Kitagawa Y; Tanahashi T; Yoshida K; Nakanishi R; Oki E; Vuzman D; Lyle S; Takabe K; Ling Y; Okuda S; Akazawa K; Wakai T
    Genome Med; 2017 Oct; 9(1):93. PubMed ID: 29089060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer.
    Zhao DY; Sun XZ; Yao SK
    World J Gastrointest Oncol; 2021 Jan; 13(1):37-57. PubMed ID: 33510848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.